Abstract:BACKGROUND AND AIMS: Therapeutic blockade of the programmed cell death protein-1 (PD-1) immune checkpoint pathways has resulted in significant reactivation of T cell-mediated antitumor immunity and is a promising clinical anticancer treatment modality in several tumor types, but the durable response rate remains relatively low (15%-20%) in most patients with HCC for unknown reasons. Evidence reveals that the interferon signaling pathway plays a critical role in modulating the efficacy and sensitivity of anti-PD-1 therapy against multiple tumor types, but the mechanisms are unclear.APPROACH AND RESULTS: Using Kaplan-Meier survival analysis based on HCC databases, we found that deceased expression of interferon regulatory factor (IRF) 8 in HCC, among all the nine IRF members that regulate interferon signals, was associated with poor prognosis of patients with HCC. Moreover, gene set enrichment analysis identified the interferon-gamma and PD-1 signaling signatures as the top suppressed pathways in patients with IRF8-low HCC. Contrarily, overexpression of IRF8 in HCC cells significantly enhanced antitumor effects in immune-competent mice, modulating infiltration of tumor-associated macrophages (TAMs) and T cell exhaustion in tumor microenvironment. We further demonstrated that IRF8 regulated recruitment of TAMs by inhibiting the expression of chemokine (C-C motif) ligand 20 (CCL20). Mechanically, IRF8-mediated repression of c-fos transcription resulted in decreased expression of CCL20, rather than directly bound to CCL20 promoter region. Importantly, adeno-associated virus 8-mediated hepatic IRF8 rescue significantly suppressed HCC progression and enhanced the response to anti-PD-1 therapy.CONCLUSIONS: This work identified IRF8 as an important prognostic biomarker in patients with HCC that predicted the response and sensitivity to anti-PD-1 therapy and uncovered it as a therapeutic target for enhancing the efficacy of immune therapy.

Key role of interferon regulatory factor 1 (IRF-1) in regulating liver disease: progress and outlook

The Role of Interferon Regulatory Factors in Liver Diseases

IRF1 Regulates the Progression of Colorectal Cancer Via Interferon‑induced Proteins.

NBR1 Mediates Autophagic Degradation of IRF3 to Negatively Regulate Type I Interferon Production.

The multiple roles of interferon regulatory factor family in health and disease

Interferon Regulatory Factors: A Key to Tumour Immunity

Progress of the interferon regulatory factors in the development of tumor

The Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Interferon Regulatory Factor 9 is a Key Mediator of Hepatic Ischemia/reperfusion Injury

Regulating IRFs in IFN Driven Disease

Clinical significance and biological function of interferon regulatory factor 1 in non-small cell lung cancer

Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy

Interferon Regulatory Factor (IRF)-1 and IRF-2 Are Associated with Prognosis and Tumor Invasion in HCC

Interferon Regulatory Factor 3 Constrains IKKβ/NF-κB Signaling to Alleviate Hepatic Steatosis and Insulin Resistance.

IRF1 Promotes the Innate Immune Response to Viral Infection by Enhancing the Activation of IRF3

IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway.

N6-methyladenosine-modified Circirf2, Identified by YTHDF2, Suppresses Liver Fibrosis Via Facilitating FOXO3 Nuclear Translocation.

IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation

Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice

Immune response gene 1 deficiency impairs Nrf2 activation and aggravates liver fibrosis in mice

IRF/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease